A new review in the Journal of Translational Medicine proposes a four-layer functional integration framework that combines ...
Prioritize viral vectors, oncology and rare disease therapies, with North America offering strong ROI potential through regulatory support, R&D investment and early adoptionDublin, Oct. 08, 2026 ...
A genome-wide screen reveals that the RNA-editing enzyme ADAR1 and the tRNA methyltransferase FTSJ1 actively drive tryptophan ...
NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Three exceptional scientists each received $250,000 – the largest unrestricted scientific award available to early-career scientists in the United States – at ...
A roundup of six recent studies explores an advanced breast cancer drug combination, atropine for childhood myopia, gene ...
Found in 70 percent of cancers, the gene is seen as a grand orchestrator but has been surprisingly difficult to stop.
A New York startup is trying to create a safe way to edit the genes of human embryos. The embryos are stored in liquid nitrogen.
Predictions for the 2026 Nobel Prizes in science highlight significant contributions in areas like GLP-1 research and cancer therapies. Carl June is mentioned for his role in developing CAR-T cell ...
Origin Genomics aims to prove the potential benefits of its technology for editing disease-causing genes in human embryos ...
CRISPR is one of this generation’s most profound innovations, with the potential to fundamentally alter the realm of modern ...
Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood ...
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. NOW PLAYING Investors Are Rotating Into Healthcare. Here's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results